Gadodiamide

Summary

Gadodiamide (CHEMBL1200346) is an approved small molecule (ATC V08CA03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08CA03
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200346
Name	Gadodiamide
Type	Small molecule
Max phase	4
ATC	V08CA03

Also known as: Gadodiamida, Gadodiamide, Gadodiamide anhydrous, GDDTPA-BMA, Omniscan, S-041, GADODIAMIDE, gadodiamide, GADODIAMIDE HYDRATE, Gadodiamide Hydrate

Parent form; salt/anhydrous children: CHEMBL3182387

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04373564	PHASE4	RECRUITING	Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT00908310	PHASE4	COMPLETED	Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
NCT04776187	PHASE4	UNKNOWN	Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
NCT00209391	PHASE3	COMPLETED	A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
NCT00209443	PHASE3	COMPLETED	A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide
NCT02501759	Not specified	TERMINATED	Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).